AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 49
- Registration Number
- NCT00313794
- Locations
- 🇨🇦
Research Site, Quebec, Canada
Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2016-12-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 933
- Registration Number
- NCT00313209
- Locations
- 🇿🇦
Altana Pharma/Nycomed Investigational Sites, Kapstadt, South Africa
🇬🇧Altana Pharma/Nycomed Investigational Site, Watford, United Kingdom
Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Carcinoma, Non-small-cell Lung
- Interventions
- Drug: best supportive care
- First Posted Date
- 2006-04-11
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 90
- Registration Number
- NCT00312975
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: exenatide, long acting release
- First Posted Date
- 2006-03-29
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 303
- Registration Number
- NCT00308139
- Locations
- 🇨🇦
Research Site, Toronto, Ontario, Canada
🇺🇸Research Site 023, Butte, Montana, United States
🇺🇸Research Site 518, San Diego, California, United States
Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™)
- First Posted Date
- 2006-03-27
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00306891
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder
- Conditions
- Post-Traumatic Stress Disorder
- Interventions
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 90
- Registration Number
- NCT00306540
- Locations
- 🇦🇺
Research Site, Melbourne, Victoria, Australia
Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101)
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 37
- Registration Number
- NCT00306163
- Locations
- 🇳🇱
Altana Pharma/Nycomed, RB Groningen, Netherlands
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg
- Conditions
- Advanced Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 143
- Registration Number
- NCT00305448
- Locations
- 🇯🇵
Research Site, Shizuoka, Japan
Effect of Quetiapine on Negative Symptoms and Cognition
- Conditions
- Schizophrenia
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2009-06-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT00305422
- Locations
- 🇩🇪
Research Site, Munich, Germany
Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101)
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 101
- Registration Number
- NCT00305461
- Locations
- 🇦🇷
Altana Pharma/Nycomed, Tucuman, Argentina